Sustained improvements in myocardial T2 over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine

Long‐term controlled studies are needed to inform on the clinical benefit of chelation therapy for myocardial iron removal in transfusion‐dependent beta thalassemia patients. In a 1‐year nonrandomized extension to the CORDELIA study, data collected from patients with myocardial siderosis provided ad...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2015-02, Vol.90 (2), p.91-96
Hauptverfasser:	Pennell, Dudley J., Porter, John B., Piga, Antonio, Lai, Yong‐Rong, El‐Beshlawy, Amal, Elalfy, Mohsen, Yesilipek, Akif, Kilinç, Yurdanur, Habr, Dany, Musallam, Khaled M., Shen, Junwu, Aydinok, Yesim
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Benzoates - adverse effects Benzoates - therapeutic use beta-Thalassemia - metabolism beta-Thalassemia - pathology beta-Thalassemia - therapy Chelation Therapy Child Confidence intervals Deferasirox Deferoxamine - adverse effects Deferoxamine - therapeutic use Drug therapy Female Hematology Humans Iron - metabolism Iron Chelating Agents - adverse effects Iron Chelating Agents - therapeutic use Iron Overload - drug therapy Iron Overload - etiology Iron Overload - metabolism Iron Overload - pathology Liver Liver - metabolism Liver - pathology Male Myocardium - metabolism Myocardium - pathology Prospective Studies Transfusion Reaction Treatment Outcome Triazoles - adverse effects Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!